Company intelligence / Profile preview

Ingenew Pharma

Evanston, Illinois, United Statesingenewpharma.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Completed a Phase 2 double-blind placebo-controlled clinical trial for hesperidin therapy in COVID-19 patients, showing a statistically significant reduction of 14.5% of Group A symptoms from 50.9% to 36.4% (p = 0.03)[5]

Therapeutic areas: OncologyDermatologyNeurologyInfectious Diseases
Modalities: Small molecules (hesperidin)proprietary formulationsdrug delivery systems
Industry: Biotech

Drug pipeline

1 asset

hesperidin

Phase 2

Indications: COVID-19

Partnerships

Montreal Health Innovations Coordinating Center (MHICC)Ortho (license agreement for drug delivery systems)

Beyond the preview

Go deeper on Ingenew Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ingenew Pharma.

Explore the full profile